AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports - Reuters
AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPMzhDZ2Y1UkxQTnZCTjg1NHdXUGZBb2Q3d3ppcnZEbWFEY1JJRWZLU0RHd1N3eDRDOVRIUXMycjdyWDNzR2pDY1ZPYXg0cFlUUWNZRWJadkt1Sld3VzZCVjN6YW1zaE1aTUt0U2x6S3p2bTRQd3dMMXc0cDhUcjJERlhyRF80YTF5My1qRmVGSU5kM3Z6bTdUcTJlS2R4TjkwM3RvdXk4eXdkYVhILWdqTS1GZlZtZ0dTZHZUMVZ5Mkk4QnI1U0lyQm1acVBfaHc?oc=5" target="_blank">AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMUniQure plunges as Huntington's trial data disappoints investors - reuters.com
UniQure plunges as Huntington's trial data disappoints investors reuters.com
September 29, 2026 at 10:11 PM